Zobrazeno 1 - 10
of 19
pro vyhledávání: '"José M Valdivielso"'
Autor:
Kunihiro Matsushita, Simerjot K Jassal, Yingying Sang, Shoshana H Ballew, Morgan E Grams, Aditya Surapaneni, Johan Arnlov, Nisha Bansal, Milica Bozic, Hermann Brenner, Nigel J Brunskill, Alex R Chang, Rajkumar Chinnadurai, Massimo Cirillo, Adolfo Correa, Natalie Ebert, Kai-Uwe Eckardt, Ron T Gansevoort, Orlando Gutierrez, Farzad Hadaegh, Jiang He, Shih-Jen Hwang, Tazeen H Jafar, Takamasa Kayama, Csaba P Kovesdy, Gijs W Landman, Andrew S Levey, Donald M Lloyd-Jones, Rupert W. Major, Katsuyuki Miura, Paul Muntner, Girish N Nadkarni, David MJ Naimark, Christoph Nowak, Takayoshi Ohkubo, Michelle J Pena, Kevan R Polkinghorne, Charumathi Sabanayagam, Toshimi Sairenchi, Markus P Schneider, Varda Shalev, Michael Shlipak, Marit D Solbu, Nikita Stempniewicz, James Tollitt, José M Valdivielso, Joep van der Leeuw, Angela Yee-Moon Wang, Chi-Pang Wen, Mark Woodward, Kazumasa Yamagishi, Hiroshi Yatsuya, Luxia Zhang, Elke Schaeffner, Josef Coresh
Publikováno v:
EClinicalMedicine, Vol 27, Iss , Pp 100552- (2020)
Background: Chronic kidney disease (CKD) measures (estimated glomerular filtration rate [eGFR] and albuminuria) are frequently assessed in clinical practice and improve the prediction of incident cardiovascular disease (CVD), yet most major clinical
Externí odkaz:
https://doaj.org/article/998af47783114dca839d455850f5705b
Autor:
Mercè Borràs Sans, Miguel Pérez-Fontán, Montserrat Martinez-Alonso, Auxiliadora Bajo, Àngels Betriu, José M Valdivielso, Elvira Fernández, NEFRONA INVESTIGATORS
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0200226 (2018)
[This corrects the article DOI: 10.1371/journal.pone.0186921.].
Externí odkaz:
https://doaj.org/article/190e71287a2e4498a28b24586723054f
Autor:
José M Valdivielso, Angels Betriu, Montserrat Martinez-Alonso, David Arroyo, Marcelino Bermudez-Lopez, Elvira Fernandez, NEFRONA investigators
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0186665 (2017)
Patients with chronic kidney disease (CKD) have an increased incidence of cardiovascular events (CVE). The contribution of subclinical atheromatosis extent, including femoral arteries, to CVE in CKD patients has not been investigated. In this paper,
Externí odkaz:
https://doaj.org/article/d38abbe63ceb4320928ea190dfda7c8b
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170654 (2017)
The final step in vitamin D activation is catalyzed by 1-alpha-hydroxylase (CYP27B1). Chronic kidney disease (CKD) is characterized by low levels of both 25(OH)D3 and 1,25(OH)2D3 provoking secondary hyperparathyroidism (2HPT). Therefore, treatments w
Externí odkaz:
https://doaj.org/article/d9fd85eaa02b4ff99e7d9b5a5d369369
Autor:
Mercè Borràs Sans, Miguel Pérez-Fontán, Montserrat Martinez-Alonso, Auxiliadora Bajo, Àngels Betriu, José M Valdivielso, Elvira Fernández, NEFRONA INVESTIGATORS
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0186921 (2017)
There is limited and inconclusive information regarding the influence of the modality of renal replacement therapy on the atherosclerotic burden of patients on dialysis. The aim of this study was to compare the prevalence of asymptomatic atheromatous
Externí odkaz:
https://doaj.org/article/9409463c10f644e58dd999e81fc97e51
Autor:
Luz M. González, Nicolás R. Robles, Sonia Mota-Zamorano, José M. Valdivielso, Laura González-Rodríguez, Juan López-Gómez, Guillermo Gervasini
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Nephrosclerosis patients are at an exceptionally high cardiovascular (CV) risk. We aimed to determine whether genetic variability represented by 38 tag-SNPs in genes of the cyclooxygenase pathway (PTGS1, PTGS2, PTGES, PTGES2 and PTGES3) lead
Externí odkaz:
https://doaj.org/article/e2f9ee43073e4063a72b693a1ad151de
Autor:
Sonia Mota-Zamorano, Luz M. González, Nicolás R. Robles, José M. Valdivielso, José C. Arévalo-Lorido, Juan López-Gómez, Guillermo Gervasini
Publikováno v:
Annals of Medicine, Vol 54, Iss 1, Pp 3039-3051 (2022)
Background Diabetic nephropathy (DN) has become the major cause of end-stage kidney disease and is associated to an extremely high cardiovascular (CV) risk.Methods We screened 318 DN patients for 23 SNPs in four glucose transporters (SLC2A1, SLC2A2,
Externí odkaz:
https://doaj.org/article/fc02b76432544e2ba0cf5139d46a9c47
Autor:
Lidia Martínez Fernández, J. Emilio Sánchez-Alvarez, César Morís de la Tassa, José Joaquín Bande Fernández, Virtudes María, Elvira Fernández, José M. Valdivielso, Angels Betriu
Publikováno v:
Nefrología, Vol 41, Iss 3, Pp 337-346 (2021)
Resumen: Introducción: Los pacientes con enfermedad renal crónica (ERC) tiene alto riesgo de morbimortalidad cardiovascular. Las alteraciones estructurales cardiacas subclínicas tienen valor pronóstico en estos pacientes. El objetivo fue estudiar
Externí odkaz:
https://doaj.org/article/e2848b8462764eef9fb9f21ec7afd776
Autor:
Patrick B Mark, Juan J Carrero, Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Morgan E Grams, Josef Coresh, Aditya Surapaneni, Nigel J Brunskill, John Chalmers, Lili Chan, Alex R Chang, Rajkumar Chinnadurai, Gabriel Chodick, Massimo Cirillo, Dick de Zeeuw, Marie Evans, Amit X Garg, Orlando M Gutierrez, Hiddo J L Heerspink, Gunnar H Heine, William G Herrington, Junichi Ishigami, Florian Kronenberg, Jun Young Lee, Adeera Levin, Rupert W Major, Angharad Marks, Girish N Nadkarni, David M J Naimark, Christoph Nowak, Mahboob Rahman, Charumathi Sabanayagam, Mark Sarnak, Simon Sawhney, Markus P Schneider, Varda Shalev, Jung-Im Shin, Moneeza K Siddiqui, Nikita Stempniewicz, Keiichi Sumida, José M Valdivielso, Jan van den Brand, Angela Yee-Moon Wang, David C Wheeler, Lihua Zhang, Frank L J Visseren, Benedicte Stengel
Publikováno v:
European Heart Journal. 44(13):1157-1166
Aims Chronic kidney disease (CKD) increases risk of cardiovascular disease (CVD). Less is known about how CVD associates with future risk of kidney failure with replacement therapy (KFRT). Methods and results The study included 25 903 761 individuals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b1c5b508c0b05035b1feed37e73661b
https://hdl.handle.net/11370/3aa20e49-9483-407e-b68e-a14656ea1fb3
https://hdl.handle.net/11370/3aa20e49-9483-407e-b68e-a14656ea1fb3
Autor:
Kunihiro Matsushita, Stephen Kaptoge, Steven H J Hageman, Yingying Sang, Shoshana H Ballew, Morgan E Grams, Aditya Surapaneni, Luanluan Sun, Johan Arnlov, Milica Bozic, Hermann Brenner, Nigel J Brunskill, Alex R Chang, Rajkumar Chinnadurai, Massimo Cirillo, Adolfo Correa, Natalie Ebert, Kai-Uwe Eckardt, Ron T Gansevoort, Orlando Gutierrez, Farzad Hadaegh, Jiang He, Shih-Jen Hwang, Tazeen H Jafar, Simerjot K Jassal, Takamasa Kayama, Csaba P Kovesdy, Gijs W Landman, Andrew S Levey, Donald M Lloyd-Jones, Rupert W Major, Katsuyuki Miura, Paul Muntner, Girish N Nadkarni, Christoph Nowak, Takayoshi Ohkubo, Michelle J Pena, Kevan R Polkinghorne, Toshimi Sairenchi, Elke Schaeffner, Markus P Schneider, Varda Shalev, Michael G Shlipak, Marit D Solbu, Nikita Stempniewicz, James Tollitt, José M Valdivielso, Joep van der Leeuw, Angela Yee-Moon Wang, Chi-Pang Wen, Mark Woodward, Kazumasa Yamagishi, Hiroshi Yatsuya, Luxia Zhang, Jannick A N Dorresteijn, Emanuele Di Angelantonio, Frank L J Visseren, Lisa Pennells, Josef Coresh
Publikováno v:
European Journal of Preventive Cardiology. 30:8-16
Aims The 2021 European Society of Cardiology (ESC) guideline on cardiovascular disease (CVD) prevention categorizes moderate and severe chronic kidney disease (CKD) as high and very-high CVD risk status regardless of other factors like age and does n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4826cebad502210fc647bf467df6a964
https://doi.org/10.1093/eurjpc/zwac176
https://doi.org/10.1093/eurjpc/zwac176